Nanozymes of Ni0.5Fe0.5S2 Mediated Synergetic Antitumor Treatment
Source abstract
Abstract
Abstract How to establish a multi‐modality oncotherapy method on the basis of single matter mediated utilization of tumor endogenous substances is very promising for efficient antitumor treatment. In this work, we have designed a metallic Ni0.5Fe0.5S2 nanosphere for synergetic chemodynamic/photodynamic/photothermal antitumor treatments. Under NIR excitation, a remarkable photothermal effect could be generated by Ni0.5Fe0.5S2 for realizing the photothermal therapy. Meanwhile, Ni0.5Fe0.5S2 could also trigger formation of reactive oxygen species (ROS) via transformation of tumor‐site oxygen for the further photodynamic therapy. Furthermore, peroxidase‐like property of Ni0.5Fe0.5S2 favors the catalysis of endogenous H2O2 into hydroxyl radical to achieve a chemodynamic therapy. As a result, the on‐site tumor hyperthermia, tumor‐site oxygen and H2O2 conversion are worked for the antitumor action. On the merits of above synergistic effect, a better antitumor outcome was confirmed as compared with any single antitumor action, and complete removal of solid tumor under a relative lower temperature has been accomplished.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Interventional Harbin Medical University Cancer Hospital 150081 Harbin Heilongjiang Province P. R. China
Department of Interventional Therapy Qinhuangdao First Hospital No. 258 Wenhua Road 066000 Qinhuangdao Hebei Province P. R. China
References (35)
Show source-provided references
1. 10.1016/j.addr.2011.03.00810.1016/j.addr.2011.03.008 ↗
2. 10.1039/C4CS00392F10.1039/C4CS00392F ↗
3. 10.1039/C6CS00616G10.1039/C6CS00616G ↗
4. 10.1016/j.jaad.2020.04.09510.1016/j.jaad.2020.04.095 ↗
5. 10.1039/C8CS00494C10.1039/C8CS00494C ↗
6. Luo D. D. · Adv. Mater. · 2017 · 4 · 1600106
7. 10.1039/C7BM01210A10.1039/C7BM01210A ↗
8. 10.1002/adma.20160415710.1002/adma.201604157 ↗
9. Yang C. · Adv. Funct. Mater. · 2018 · 28 · 201706827
10. 10.1038/nrc107110.1038/nrc1071 ↗
11. 10.1021/cr500419810.1021/cr5004198 ↗
12. 10.1021/nn102722z10.1021/nn102722z ↗
13. 10.1016/j.cej.2019.12396110.1016/j.cej.2019.123961 ↗
14. 10.1021/jacs.9b1155310.1021/jacs.9b11553 ↗
15. 10.1016/j.jcis.2020.08.05910.1016/j.jcis.2020.08.059 ↗
16. 10.1002/adma.20130525610.1002/adma.201305256 ↗
17. 10.1021/ja404985w10.1021/ja404985w ↗
18. 10.1021/acsnano.5b0582510.1021/acsnano.5b05825 ↗
19. 10.1002/ange.20181248210.1002/ange.201812482 ↗
20. 10.1021/nn500211210.1021/nn5002112 ↗
21. 10.1002/advs.20170089110.1002/advs.201700891 ↗
22. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
23. 10.1016/j.cej.2019.12392510.1016/j.cej.2019.123925 ↗
24. 10.1021/accountsmr.1c0007410.1021/accountsmr.1c00074 ↗
25. 10.1016/j.mattod.2020.08.02010.1016/j.mattod.2020.08.020 ↗
26. 10.1016/j.nantod.2021.10126910.1016/j.nantod.2021.101269 ↗
27. 10.1021/acsnano.1c0124810.1021/acsnano.1c01248 ↗
28. 10.1016/j.nantod.2021.10131710.1016/j.nantod.2021.101317 ↗
29. 10.1039/D0NR02800B10.1039/D0NR02800B ↗
30. 10.1002/adfm.20211026810.1002/adfm.202110268 ↗
31. 10.1002/EXP.2021000510.1002/EXP.20210005 ↗
32. 10.3389/fchem.2020.0049110.3389/fchem.2020.00491 ↗
33. 10.1039/D1TB00544H10.1039/D1TB00544H ↗
34. 10.1039/C9NJ03560E10.1039/C9NJ03560E ↗
35. 10.1039/c3cc40625c10.1039/c3cc40625c ↗